• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

by Rakovina Therapeutics | Aug 26, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, August 26, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through Al-powered drug discovery, today announced...

Rakovina Therapeutics Announces Warrant Exercise Incentive Program

by Rakovina Therapeutics | Aug 21, 2025 | Uncategorized

DOWNLOAD VANCOUVER, BC, July 24, 2025 Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company” or “Rakovina”) a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announced...

Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging Al-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

by Rakovina Therapeutics | Aug 13, 2025 | Uncategorized

DOWNLOAD KT-3283, a duel PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field Vancouver, British Columbia & Riyadh, Saudi Arabia August 12, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or...

Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

by Rakovina Therapeutics | Aug 1, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, July 30, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to highlight...

Rakovina Therapeutics KT-5000Al Program Yields Potent ATR Inhibitor Hits in Early Screening

by Rakovina Therapeutics | Jul 24, 2025 | Uncategorized

DOWNLOAD Compounds developed through collaboration with Variational Al show targeted activity Vancouver, British Columbia, July 23, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media